86-21-64556180

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
FAQs
Contact Us

Home
SM-04690

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
- DPP-4
- SGLT-1
- SGLT-2
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

SM-04690 - Manufacturers, Factory, Suppliers From China

SM-04690, , , , SM-04690,

Factory supplied 5a-hydroxy Laxogenin - CB-839...
Discount wholesale Factory Albendazole Price - ...
Supply OEM High Quality Curcumin Antineoplastic...
China Manufacturer for 6 – Efinaconazole ...
Supply OEM Bulk Nicotinamide Riboside - Nazart...
Factory Price Derazantinib - CAS: 1802253-30-0...
Short Lead Time for BLU554 - T-26c – Cae...
Factory directly 7 Adrafinil Price – Cas ...

<< < Previous 1 2

Contact Us

3rd Floor, Building 4, 3918 Daye Road, Fengxian District, Shanghai
86-21-64556180
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...
ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...
AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !